Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 1420-1428, 2016.
Article
in English
| WPRIM
| ID: wpr-205894
ABSTRACT
PURPOSE:
This study reported patient outcomes of chemotherapy-induced nausea and vomiting (CINV) prophylaxis for highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC) regimens and evaluated its adherence to acute-phase CINV prophylaxis in the Korean population subset of the Pan Australasian Chemotherapy Induced Emesis burden of illness (PrACTICE) study. MATERIALS ANDMETHODS:
This subgroup analysis evaluated 158 Korean patients receiving HEC or MEC and compared the data (wherever possible) with that of 648 patients from the Asia-Pacific (AP) region. Study endpoints included evaluation of primary CINV prophylaxis and adherence to acute-phase CINV prophylaxis in cycle 1 (American Society of Clinical Oncology [ASCO] Quality Oncology Practice Initiative [QOPI]).RESULTS:
In South Korea and the AP, a 5-hydroxytryptamine-3 receptor antagonist (5HT₃-RA) prophylaxis for the acute phase was administered to 79/80 patients (98.8%) for HEC and 70/71 patients (98.6%) for MEC regimens (QOPI-1). Triple regimen (corticosteroid–5HT₃-RA–neurokinin 1-RA) was initiated in 46/80 patients (57.5%) for prophylaxis of acute CINV in cycle 1 of HEC (QOPI-3). Double regimen (corticosteroid–5HT₃-RA, with or within NK₁-RA) was initiated in 61/71 patients (83.1%) for control of acute CINV in cycle 1 of MEC a(QOPI-2).CONCLUSION:
Active management of CINV is necessary in cycle 1 of HEC in South Korea, despite higher rates than the AP region. Adherence to the international guidelines for CINV prophylaxis requires attention in the acute phase in cycle 1 of the HEC regimen.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Vomiting
/
Cost of Illness
/
Receptors, Serotonin, 5-HT3
/
Drug Therapy
/
Korea
/
Medical Oncology
/
Antiemetics
/
Nausea
Type of study:
Practice guideline
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Cancer Research and Treatment
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS